B3B

About B3B

This author has not yet filled in any details.
So far B3B has created 225 entries.

Gilead Takes ‘Low Road’

Full feature

More coverage:

TheStreet: Gilead Sciences Bucks Tradition, Takes ‘Low Road’ on New Hepatitis C Drug Price More
FierceBiotech: New Gilead hep C combo Epclusa gains FDA approval More
STAT: FDA approves a Gilead pill that is first to treat all forms of hepatitis C More

June 29th, 2016|

Event Recap: Medical Devices Take the Spotlight

By Marie Daghlian; Photos by Eugene Borodin

A smart contact lens that monitors blood glucose, video games that promise to enhance cognition, a novel and simple biopsy device that improves patient comfort—these are just a few of the next generation of medical devices showcased at the third annual Rosenman Institute Symposium, held June 22nd at Byers […]

June 29th, 2016|

KaloBios Reinvents Itself and How to Price Drugs

From The Bio Report/Daniel Levine: “KaloBios, a biotech best known for a series of disastrous events including failed clinical trials, a bankruptcy filing, lawsuits, and the arrest of its CEO, is being reborn. In the process, it may provide a valuable contribution to the ongoing discussion over drug pricing. In April, the development-stage company […]

June 23rd, 2016|

Event Recap: ISSCR Conference

By Dr. Karen Ring for CIRM/Big3Bio:

CIRM kicked off the 2016 International Society for Stem Cell Research (ISSCR) Conference in San Francisco with a public stem cell event yesterday that brought scientists, patients, patient advocates and members of the general public together to discuss the many ways stem cells are being used in the clinic […]

June 23rd, 2016|

This Bloody Plant Burger Smells, Tastes And Sizzles Like Meat

From NPR:

“This summer, diners in New York, San Francisco and Los Angeles will get their hands on a hamburger that has been five years in the making.

The burger looks, tastes and smells like beef — except it’s made entirely from plants. It sizzles on the grill and even browns and oozes fat when it […]

June 21st, 2016|

Sean Parker to Fund Groundbreaking CRISPR Trial

UPDATE: A federal ethics and biosafety panel has approved the trial – coverage:

Nature: First CRISPR clinical trial gets green light from US panel
STAT: Federal panel approves first use of CRISPR in humans

PREVIOUS: Internet billionaire Sean Parker is funding the first proposed test of CRISPR gene-editing technology in human beings. It would mark the first clinical trial involving CRISPR.

Excerpts of […]

June 21st, 2016|

Cerus Wins Up-to-$180.5M BARDA Contract

Excerpt of coverage from GEN:

“Under the BARDA contract, Cerus will receive initial funding of up to $30,750,939 to support activities related to a clinical trial to assess the safety and efficacy of Intercept RBCs compared to conventional RBCs in Puerto Rico, which has been impacted by the Zika virus epidemic. This funding also will […]

June 20th, 2016|

Using Technology to Modernize Preclinical Development

From The Bio Report/Daniel Levine: “Despite a rapid advance of technology there’s been little change in the preclinical drug development process. Vium is hoping to change that by using sensors, automation, and bioinformatics to change the way data is gathered in the preclinical process to fuel better and faster decisions about the potential value […]

June 17th, 2016|

Google Ventures CEO on A.I., Theranos, Biotech & VC

From Bloomberg: “Bill Maris, CEO Google Ventures, comments on artificial intelligence’s impact on biotech, the prospects for Theranos and the venture capital environment. He speaks with Bloomberg’s Emily Chang on “Bloomberg West” from the Bloomberg Technology Conference in San Francisco.”

June 14th, 2016|

Merck to Acquire Afferent Pharmaceuticals

From Merck press release:

“Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for […]

June 10th, 2016|
X